Pfizer cuts 2022 earnings outlook despite strong first-quarter Covid vaccine and antiviral sales
Pfizer said it sold $13.2 billion of its Covid vaccine and $1.5 billion of its antiviral treatment Paxlovid.
Office demand comes roaring back as stocks in the space play catch-up
After a five-month lull due to the omicron variant, office demand is surging back again, albeit slowly for the office stocks.
Paxlovid prescriptions to treat Covid increased tenfold in U.S. since late February, Pfizer says
CEO Albert Bourla said Paxlovid prescriptions in the U.S. increased to 80,000 patients for the week ending April 22, up from 8,000 patients in late...
S&P 500 rises slightly in choppy trading ahead of Fed decision
Investors are coming off a wild up-and-down session for stocks, with the S&P 500 rising on Monday after hitting a new 2022 low.
Uber reports first-quarter earnings on Wednesday: Here’s what Wall Street’s watching
Uber shares are down more than 26% year to date. Here's what Wall Street will be looking for when Uber reports first-quarter earnings on Wednesday.
BP reports bumper first-quarter net profit, but posts massive loss on hit from Russia exit
BP announced a further $2.5 billion in share buybacks as it reported its highest first-quarter profit in more than a decade.
Burger King parent earnings beat estimates as revenue climbs 15%
Restaurant Brands International reported results that beat expectations, fueled by strong same-store sales growth from Burger King's overseas restaurants.
Pfizer cuts 2022 earnings outlook despite strong first-quarter Covid vaccine and antiviral sales
Pfizer said it sold $13.2 billion of its Covid vaccine and $1.5 billion of its antiviral treatment Paxlovid.
The Federal Reserve’s fight with inflation could cool the hot labor market, risking stagflation
Prices are rising as the Fed winds down a historic round of stimulus. This tightening cycle could slow jobs growth as global markets ride a...